3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
5
von Hippel-Lindau Disease
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Interventions
Blood Specimen Collection
2
gallium Ga 68 dotatate
1
belzutifan
1
Sunitinib
1
Propranolol
1
Magnetic Resonance Spectroscopy
1
Exome Sequencing
1
Bevacizumab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
von Hippel-Lindau Disease
×
belzutifan
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled